Cancer Radiotherapie最新文献

{"title":"Radiotherapy in the management of lung oligometastases","authors":"V. Bourbonne ,&nbsp;A. Lévy ,&nbsp;J. Khalifa ,&nbsp;D. Antoni ,&nbsp;E. Blais ,&nbsp;J. Darréon ,&nbsp;C. Le Péchoux ,&nbsp;D. Lerouge ,&nbsp;P. Giraud ,&nbsp;A. Marguerit ,&nbsp;N. Pourel ,&nbsp;F.-G. Riet ,&nbsp;S. Thureau","doi":"10.1016/j.canrad.2023.06.030","DOIUrl":"10.1016/j.canrad.2023.06.030","url":null,"abstract":"<div><p>In recent years, the development of both medical imaging and new systemic agents (targeted therapy and immunotherapy) have revolutionized the field of oncology, leading to a new entity: oligometastatic disease. Adding local treatment of oligometastases to systemic treatment could lead to prolonged survival with no significant impact on quality of life. Given the high prevalence of lung oligometastases and the new systemic agents coming with increased pulmonary toxicity, this article provides a comprehensive review of the current state-of-art for radiotherapy of lung oligometastases. After reviewing pretreatment workup, the authors define several radiotherapy regimen based on the localization and size of the oligometastases. A comment on the synergistic combination of medical treatment and radiotherapy is also made, projecting on future steps in this specific clinical setting.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 36-48"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation therapy of the primary tumour and/or metastases of digestive metastatic cancers","authors":"F. Huguet ,&nbsp;O. Riou ,&nbsp;D. Pasquier ,&nbsp;A. Modesto ,&nbsp;L. Quéro ,&nbsp;M. Michalet ,&nbsp;A. Bordron ,&nbsp;B. Schipman ,&nbsp;A. Orthuon ,&nbsp;A. Lisbona ,&nbsp;V. Vendrely ,&nbsp;N. Jaksic","doi":"10.1016/j.canrad.2023.04.007","DOIUrl":"10.1016/j.canrad.2023.04.007","url":null,"abstract":"<div><p>Metastatic gastrointestinal cancer is not an uncommon situation, especially for pancreatic, gastric, and colorectal cancers. In this setting, few data are available on the impact of the treatment of the primary tumour. Oligometastatic disease is associated with longer survival in comparison with more advanced disease. Metastasis-directed therapy, such as stereotactic body radiotherapy, seems related to better outcomes, but the level of evidence is low. In most tumour locations, prospective data are very scarce and inclusion in ongoing trials is strongly recommended.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 66-74"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41175602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy in the management of synchronous metastatic lung cancer","authors":"J. Khalifa ,&nbsp;A. Lévy ,&nbsp;L.-M. Sauvage ,&nbsp;S. Thureau ,&nbsp;J. Darréon ,&nbsp;C. Le Péchoux ,&nbsp;D. Lerouge ,&nbsp;N. Pourel ,&nbsp;D. Antoni ,&nbsp;E. Blais ,&nbsp;É. Martin ,&nbsp;A. Marguerit ,&nbsp;P. Giraud ,&nbsp;F.-G. Riet","doi":"10.1016/j.canrad.2023.03.002","DOIUrl":"10.1016/j.canrad.2023.03.002","url":null,"abstract":"<div><p>Metastatic lung cancer classically portends a poor prognosis. The management of metastatic lung cancer has dramatically changed with the emergence of immune checkpoint inhibitors, targeted therapy and due to a better understanding of the oligometastatic process. In metastatic lung cancers, radiation therapy which was only used with palliative intent for decades, represents today a promising way to treat primary and oligometastatic sites with a curative intent. Herein we present through a literature review the role of radiotherapy in the management of synchronous metastatic lung cancers.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 22-35"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9981475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations","authors":"L. Ollivier ,&nbsp;K. Debbi ,&nbsp;N.-H. To ,&nbsp;A. Cailleteau ,&nbsp;S. Supiot ,&nbsp;A. Mervoyer ,&nbsp;V. Guimas ,&nbsp;Y. Belkacémi","doi":"10.1016/j.canrad.2023.08.008","DOIUrl":"10.1016/j.canrad.2023.08.008","url":null,"abstract":"<div><h3>Purpose</h3><p>Haematologic malignancies are particular in that they can generally be cured, even when distant metastases are present at diagnosis, unlike solid malignancies. Systemic treatments, including chemotherapy, targeted therapies, and immunotherapy, are the standard of care with excellent results. The considerable progress made in the management of these diseases in the last 20<!--> <!-->years has redefined the role of radiation therapy as minor in many clinical situations. We propose a literature review of data, showing that radiation therapy still has a role in curative, salvage, and palliative therapy situations.</p></div><div><h3>Material and methods</h3><p>A document and literature search was carried out in the following databases: Medline and ClinicalTrial.gov, for the terms “radiotherapy”, “haematologic malignancies”, “Hodgkin lymphoma”, “non-Hodgkin lymphoma”, “CAR T cells”, “multiple myeloma”, “solitary plasmocytoma”, “intensity-modulated radiotherapy”, “extracranial stereotactic body radiation therapy” and “proton therapy references”.</p></div><div><h3>Results</h3><p>Haemopathological malignancies include a wide range of diseases and radiation therapy indications have been assessed over the past 20<!--> <!-->years. Currently, radiation therapy is indicated for localized disease (solitary plasmocytoma), as an adjuvant (Hodgkin lymphoma), in palliative settings, or after systemic treatment in relapsed patients (chimeric antigen receptor [CAR] T-cells) with a low recurrence burden, which can therefore be considered “oligorecurrence”. Radiation therapy, through total body irradiation, has important indications, thanks to its immunomodulatory and/or myeloablative effects. Moreover, recent technological developments have made possible significant improvement in safety, contributing to radiation therapy being positioned in the treatment strategy of several indications.</p></div><div><h3>Conclusions</h3><p>Given the effectiveness of systemic treatments in hematologic malignancies, the oligometastasis stage is of little importance. A curative intent after local radiation therapy, even advanced stage, is possible, both with residual disease for advanced Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or solitary plasmocytoma, and even without evidence of disease after chemotherapy for Hodgkin or non-Hodgkin lymphoma. The role of new treatments, such as CAR T cells, allows us to consider radiation therapy after systemic treatment of relapsed diseases with low volume recurrence, which can be considered oligorecurrence.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 119-130"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1278321823002421/pdfft?md5=0e75d8b99c1a7369873754d578ee6abb&pid=1-s2.0-S1278321823002421-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139031511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of radiotherapy in the management of brain oligometastases","authors":"D. Antoni ,&nbsp;E. Mesny ,&nbsp;O. El Kabbaj ,&nbsp;S. Josset ,&nbsp;G. Noël ,&nbsp;J. Biau ,&nbsp;L. Feuvret ,&nbsp;I. Latorzeff","doi":"10.1016/j.canrad.2023.03.005","DOIUrl":"10.1016/j.canrad.2023.03.005","url":null,"abstract":"<div><p>The management of patients with brain oligometastases is complex and relies on specific reasoning compared to extracranial oligometastases. The levels of evidence are still low because patients with brain oligometastases are frequently excluded from randomized clinical trials. Stereotactic radiotherapy should be preferred in this indication over whole brain irradiation, both for patients with metastases in place and for those who have undergone surgery. The decision of local treatment and its timing must be a multidisciplinary reflection taking into account the histological and molecular characteristics of the tumor as well as the intracranial efficacy of the prescribed systemic treatments. Great caution must be observed when using stereotactic radiotherapy and concomitant systemic treatments because interactions are still poorly documented. We present the recommendations of the French society of radiation oncology on the management of brain oligometastatic patients with radiotherapy.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 103-110"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41176266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy management of paediatric cancers with synchronous metastasis","authors":"L. Claude ,&nbsp;J. Bouter ,&nbsp;G. Le Quellenec ,&nbsp;L. Padovani ,&nbsp;A. Laprie","doi":"10.1016/j.canrad.2023.03.003","DOIUrl":"10.1016/j.canrad.2023.03.003","url":null,"abstract":"<div><p>Cancer in childhood represent 1% of all the new diagnosed cancers. About 30% of children with cancer receive radiation therapy, representing about 600 to 700 patients per year in France. As a consequence, paediatric cancers with synchronous metastasis is a very rare situation in oncology, with usually poor standard of care. However, considerable efforts are made by paediatric oncology scientific societies to offer trials or treatment consensus despite these rare situations. The article proposes to synthesize the radiotherapy management of both primary tumour and synchronous metastasis in the most “common” childhood or adolescent cancers.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 131-140"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10073463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of head and neck carcinomas with synchronous or metachronous oligometastatic disease: Role of locoregional radiotherapy and metastasis-directed radiotherapy","authors":"M. Tonneau ,&nbsp;R. Nebbache ,&nbsp;A. Larnaudie ,&nbsp;S. Thureau ,&nbsp;Y. Pointreau ,&nbsp;P. Blanchard ,&nbsp;J. Thariat","doi":"10.1016/j.canrad.2023.03.004","DOIUrl":"10.1016/j.canrad.2023.03.004","url":null,"abstract":"<div><p>Head and neck carcinomas are initially metastatic in about 15% of cases. Radiotherapy is a cornerstone in the multimodal strategy at the locoregional phase. In patients with head and neck cancer, often heavily pretreated and with comorbidities, who relapse locoregionally or at distant sites, radiotherapy has also become increasingly important at the metastatic phase. Data on the optimal sequence of systemic treatments and metastasis-directed treatments including stereotactic irradiation are still lacking. Several randomized head and neck trials have been initiated that should provide important answers, including one recent GORTEC trial.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 83-92"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10123577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation therapy of the primary tumour and oligometastatic sites in patients with breast cancer with synchronous metastases: A literature review","authors":"R. Le Scodan ,&nbsp;Y. Ghannam ,&nbsp;Y. Kirova ,&nbsp;C. Bourgier ,&nbsp;A. Richard Tallet","doi":"10.1016/j.canrad.2023.08.007","DOIUrl":"10.1016/j.canrad.2023.08.007","url":null,"abstract":"<div><p>De novo metastatic breast cancer represents 5 to 8% of all breast cancers (2500 new cases per year in France). Systemic treatment is the cornerstone of treatment, whereas radiation therapy usually has a palliative intent. Advances in systemic and local treatments (surgery and radiation therapy) have substantially improved overall survival. In the recent breast cancer statistics in the United States, the 5-year relative survival for patients diagnosed during 2012–2018 was 29% for stage IV (Breast Cancer Statistics). Thus, an increasing proportion of metastatic breast cancers present a prolonged complete response to systemic therapy, which raises the question of the impact of local treatment on patient survival. Radiation therapy has shown its value for early breast cancer, but its place in the local management of the primary tumour or oligometastatic sites for de novo metastatic breast cancer remains under debate. This article is a literature review assessing the role of radiation therapy directed to the primary tumour and oligometastatic sites of breast cancer in patients with synchronous metastases<del>,</del> in order to highlight clinicians in their therapeutic decision.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 3-14"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138557167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of radiation therapy for de novo metastatic bladder and renal cancers","authors":"P. Sargos ,&nbsp;J. Le Guevelou ,&nbsp;J. Khalifa ,&nbsp;L. Albiges ,&nbsp;D. Azria ,&nbsp;R. de Crevoisier ,&nbsp;S. Supiot ,&nbsp;G. Créhange ,&nbsp;G. Roubaud ,&nbsp;O. Chapet ,&nbsp;D. Pasquier ,&nbsp;P. Blanchard ,&nbsp;I. Latorzeff","doi":"10.1016/j.canrad.2023.02.004","DOIUrl":"10.1016/j.canrad.2023.02.004","url":null,"abstract":"<div><p>Metastatic bladder and renal cancers account respectively for 2.1% and 1.8% of cancer deaths worldwide. The advent of immune checkpoint inhibitors has revolutionized the management of metastatic disease, by demonstrating considerable improvements in overall survival. However, despite initial sensitivity to immune checkpoint inhibitors for most patients, both bladder and renal cancer are associated with short progression-free survival and overall survival, raising the need for further strategies to improve their efficacy. Combining systemic therapies with local approaches is a longstanding concept in urological oncology, in clinical settings including both oligometastatic and polymetastatic disease. Radiation therapy has been increasingly studied with either cytoreductive, consolidative, ablative or immune boosting purposes, but the long-term impact of this strategy remains unclear. This review intends to address the impact of radiation therapy with either curative or palliative intent, for synchronous de novo metastatic bladder and renal cancers.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 56-65"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9590445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiation therapy for liver metastases in oligometastatic disease","authors":"N. Jaksic ,&nbsp;A. Modesto ,&nbsp;N. Meillan ,&nbsp;A. Bordron ,&nbsp;M. Michalet ,&nbsp;O. Riou ,&nbsp;A. Lisbona ,&nbsp;F. Huguet","doi":"10.1016/j.canrad.2023.04.008","DOIUrl":"10.1016/j.canrad.2023.04.008","url":null,"abstract":"<div><p>Oligometastatic cancers designate cancers in which the number of metastases is less than five, corresponding to a particular biological entity whose prognosis is situated between a localized and metastatic disease. The liver is one of the main sites of metastases. When patients are not suitable for surgery, stereotactic body radiotherapy provides high local control rate, although these data come mainly from retrospective studies, with no phase III study results. The need for a high therapeutic dose (biologically effective dose greater than 100<!--> <!-->Gy) while respecting the constraints on the organs at risk, and the management of respiratory movements require expertise and sufficient technical prerequisites. The emergence of new techniques such as MRI-guided radiotherapy could further increase the effectiveness of stereotactic radiotherapy of liver metastases, and thus improve the prognosis of these oligometastatic cancers.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 1","pages":"Pages 75-82"},"PeriodicalIF":1.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}